First contingency description of the classification nomenclature for the marketed drugs screened for MDR1 transport and inhibition used within the manuscript
↵a Number of compounds marketed for CNS indications.
↵b Number of compounds marketed for non-CNS indications.
↵c Total number of compounds tested.